US8669246B2 - Substituted amide compound - Google Patents

Substituted amide compound Download PDF

Info

Publication number
US8669246B2
US8669246B2 US13/498,159 US201013498159A US8669246B2 US 8669246 B2 US8669246 B2 US 8669246B2 US 201013498159 A US201013498159 A US 201013498159A US 8669246 B2 US8669246 B2 US 8669246B2
Authority
US
United States
Prior art keywords
substituted
lower alkyl
compound
halogen
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US13/498,159
Other languages
English (en)
Other versions
US20120184521A1 (en
Inventor
Eiji Kawaminami
Tatsuhisa Takahashi
Takatoshi Kanayama
Yuta Fukuda
Hiroyuki Kaizawa
Yutaka Kondoh
Ryushi Seo
Kazuyuki Kuramoto
Kazuhiko Take
Kazuyuki Sakamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Assigned to ASTELLAS PHARMA INC. reassignment ASTELLAS PHARMA INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FUKUDA, YUTA, KAIZAWA, HIROYUKI, KANAYAMA, TAKATOSHI, KAWAMINAMI, EIJI, KONDOH, YUTAKA, KURAMOTO, KAZUYUKI, SAKAMOTO, KAZUYUKI, SEO, RYUSHI, TAKAHASHI, TATSUHISA, TAKE, KAZUHIKO
Publication of US20120184521A1 publication Critical patent/US20120184521A1/en
Application granted granted Critical
Publication of US8669246B2 publication Critical patent/US8669246B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
US13/498,159 2009-09-25 2010-09-24 Substituted amide compound Active US8669246B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009-220316 2009-09-25
JP2009220316 2009-09-25
PCT/JP2010/066572 WO2011037192A1 (ja) 2009-09-25 2010-09-24 置換アミド化合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2010/066572 A-371-Of-International WO2011037192A1 (ja) 2009-09-25 2010-09-24 置換アミド化合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/783,858 Continuation US8815920B2 (en) 2009-09-25 2013-03-04 Substituted amide compound

Publications (2)

Publication Number Publication Date
US20120184521A1 US20120184521A1 (en) 2012-07-19
US8669246B2 true US8669246B2 (en) 2014-03-11

Family

ID=43795936

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/498,159 Active US8669246B2 (en) 2009-09-25 2010-09-24 Substituted amide compound
US13/783,858 Active US8815920B2 (en) 2009-09-25 2013-03-04 Substituted amide compound

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/783,858 Active US8815920B2 (en) 2009-09-25 2013-03-04 Substituted amide compound

Country Status (17)

Country Link
US (2) US8669246B2 (pt)
EP (1) EP2481725B1 (pt)
JP (1) JP5708936B2 (pt)
KR (1) KR101678255B1 (pt)
CN (1) CN102548965B (pt)
AU (1) AU2010299114A1 (pt)
BR (2) BR112012006686B8 (pt)
CA (1) CA2774647C (pt)
ES (1) ES2532866T3 (pt)
IL (1) IL218723A0 (pt)
MX (1) MX2012003560A (pt)
PL (1) PL2481725T3 (pt)
PT (2) PT2481725E (pt)
RU (2) RU2609021C2 (pt)
TW (1) TW201117809A (pt)
WO (1) WO2011037192A1 (pt)
ZA (1) ZA201202106B (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201117809A (en) 2009-09-25 2011-06-01 Astellas Pharma Inc Substituted amide compounds
ES2537726T3 (es) * 2010-09-24 2015-06-11 Astellas Pharma Inc. Compuesto de amida sustituida
HU1000676D0 (en) * 2010-12-17 2011-02-28 Pharmahungary 2000 Kft Inhibitors of matrix metalloproteinase, pharmaceutical compositions thereof and use of them for preventing and treating diseases where the activation of mmp is involved
WO2013025733A1 (en) 2011-08-15 2013-02-21 Intermune, Inc. Lysophosphatidic acid receptor antagonists
RU2014121984A (ru) 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Бензолсульфонамидные соединения и их применение в качестве терапевтических средств
BR112014010368A2 (pt) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc biaril éter sulfonamidas e seu uso como agentes terapêuticos
ES2593533T3 (es) * 2011-12-15 2016-12-09 Pfizer Limited Derivados de sulfonamida
MX2014014234A (es) 2012-05-22 2015-05-07 Genentech Inc Benzamidas n-sustituidas y su uso en el tratamiento del dolor.
KR101663436B1 (ko) * 2012-07-06 2016-10-06 제넨테크, 인크. N-치환된 벤즈아미드 및 이의 사용 방법
CN103102325B (zh) * 2013-01-16 2014-11-12 浙江大学宁波理工学院 一种2-溴代甲基-4-羧酸乙酯噻唑的合成方法
RU2015143906A (ru) 2013-03-14 2017-04-18 Дженентек, Инк. Замещенные триазолопиридины и способы их применения
PT2968440T (pt) 2013-03-15 2019-07-31 Zymeworks Inc Compostos citotóxicos e antimitóticos e métodos de utilização dos mesmos
MX2015010775A (es) 2013-03-15 2016-04-25 Genentech Inc Benzoxazoles sustituidos y metodos para usarlos.
CN103467281B (zh) * 2013-07-25 2016-03-23 武汉英纳氏药业有限公司 一种苯酚衍生物及其应用
GB201314926D0 (en) 2013-08-20 2013-10-02 Takeda Pharmaceutical Novel Compounds
CA2931732A1 (en) 2013-11-27 2015-06-04 Genentech, Inc. Substituted benzamides and methods of use thereof
ES2916722T3 (es) * 2013-12-27 2022-07-05 Zymeworks Inc Sistemas de enlace que contienen sulfonamida para conjugados de fármacos
MX2016008448A (es) 2013-12-27 2017-01-09 Zymeworks Inc Conjugados de var2csa-farmaco.
CN106715418A (zh) 2014-07-07 2017-05-24 基因泰克公司 治疗化合物及其使用方法
IL287645B2 (en) 2014-09-17 2024-04-01 Zymeworks Bc Inc Cytotoxic and anti-mitotic compounds and methods for their use
EP3733209A1 (en) * 2014-10-03 2020-11-04 Synaffix B.V. Sulfamide linker, conjugates thereof, and methods of preparation
BR112017024853A2 (pt) 2015-05-22 2018-08-07 Genentech Inc composto, composição farmacêutica, método para tratar uma doença ou condição em um mamífero, para tratamento de prurido em um mamífero, para tratamento ou profilaxia e uso de um composto
CN106243003B (zh) * 2015-06-03 2018-03-09 上海海雁医药科技有限公司 环烃基取代的甲磺酰基苯甲酰胺衍生物、其制法与医药上的用途
US10253131B2 (en) * 2015-07-13 2019-04-09 University Of Delaware Polymers prepared from functionalized dimethoxyphenol monomers
US11525024B2 (en) 2015-07-13 2022-12-13 University Of Delaware Bio-based polymers from raw lignocellulosic biomass
EP3341353A1 (en) 2015-08-27 2018-07-04 Genentech, Inc. Therapeutic compounds and methods of use thereof
CN105085244A (zh) * 2015-08-31 2015-11-25 彭静 一种r-4-溴苦杏仁酸的制备方法
CN105085234A (zh) * 2015-08-31 2015-11-25 彭静 一种r-4-氯扁桃酸的制备方法
CN105085245A (zh) * 2015-08-31 2015-11-25 彭静 一种r-4-氟扁桃酸的制备方法
CN105085235A (zh) * 2015-08-31 2015-11-25 彭静 拆分制备s-4-氯扁桃酸的方法
CN105152913A (zh) * 2015-08-31 2015-12-16 彭静 S-4-氟扁桃酸的制备方法
CN105085246A (zh) * 2015-09-02 2015-11-25 彭静 一种r-邻氯扁桃酸的制备方法
CN105085236A (zh) * 2015-09-02 2015-11-25 彭静 R-五氟苦杏仁酸的拆分制备方法
CN105085247A (zh) * 2015-09-02 2015-11-25 彭静 拆分制备r-4-甲氧基扁桃酸的方法
CN105085248A (zh) * 2015-09-02 2015-11-25 彭静 拆分制备s-4-甲氧基扁桃酸的方法
CN105061190A (zh) * 2015-09-02 2015-11-18 彭静 拆分制备s-五氟苦杏仁酸的方法
JP6987746B2 (ja) 2015-09-28 2022-01-05 ジェネンテック， インコーポレイテッド 治療用化合物及びその使用方法
EP3380466A1 (en) 2015-11-25 2018-10-03 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
EP3413922A1 (en) * 2016-02-08 2018-12-19 SynAffix B.V. Improved sulfamide linkers for use in bioconjugates
CN109069658B (zh) 2016-02-08 2022-10-14 西纳福克斯股份有限公司 用于靶向her2肿瘤的具有改善的治疗指数的抗体-缀合物以及用于改善抗体-缀合物的治疗指数的方法
EP3413920A1 (en) 2016-02-08 2018-12-19 Synaffix B.V. Bioconjugates containing sulfamide linkers for use in treatment
EP3854782A1 (en) 2016-03-30 2021-07-28 Genentech, Inc. Substituted benzamides and methods of use thereof
CA3039853A1 (en) 2016-10-17 2018-04-26 Genentech, Inc. Therapeutic compounds and methods of use thereof
EP3601273B1 (en) 2017-03-24 2021-12-01 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
AR114263A1 (es) 2018-02-26 2020-08-12 Genentech Inc Compuestos terapéuticos y métodos para utilizarlos
US10947251B2 (en) 2018-03-30 2021-03-16 Genentech, Inc. Therapeutic compounds and methods of use thereof
HUE061559T2 (hu) * 2018-06-07 2023-07-28 Idorsia Pharmaceuticals Ltd Alkoxi-helyettesített piridinil származékok mint LAP1 receptor antagonisták és fibrózis kezelésében való alkalmazásuk
AR119162A1 (es) * 2019-06-18 2021-12-01 Idorsia Pharmaceuticals Ltd Derivados de piridin-3-ilo
EP4011982A4 (en) 2019-08-09 2022-11-23 Konica Minolta, Inc. RESIN COMPOSITION, FILAMENTAL MATERIAL, THREE-DIMENSIONAL; GENERATIVELY MANUFACTURED OBJECT AND METHOD FOR MANUFACTURING A THREE-DIMENSIONAL, GENERATIVELY MANUFACTURED OBJECT
AU2020384883B2 (en) 2019-11-15 2023-11-16 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
TW202344504A (zh) 2020-06-03 2023-11-16 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
CN115867556A (zh) 2020-06-03 2023-03-28 吉利德科学公司 Lpa受体拮抗剂及其用途
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
WO2024089216A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Novel sulfur-containing heteroaryl carboxamide compounds

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060819A1 (fr) 2000-02-18 2001-08-23 Kirin Beer Kabushiki Kaisha Nouveaux composes d'isoxazole et de thiazole et leur utilisation en tant que medicaments
WO2002062389A1 (fr) 2001-02-08 2002-08-15 Ono Pharmaceutical Co., Ltd. Remedes pour des maladies urinaires contenant des agents de regulation du recepteur de lpa
WO2003099765A1 (fr) 2002-05-28 2003-12-04 Ono Pharmaceutical Co., Ltd. Derive de $g(b)-alanine et utilisation correspondante
WO2004002530A1 (ja) 2002-06-26 2004-01-08 Ono Pharmaceutical Co., Ltd. 慢性疾患治療剤
WO2004031118A1 (ja) 2002-10-03 2004-04-15 Ono Pharmaceutical Co., Ltd. Ｌｐａ受容体拮抗剤
WO2005058790A1 (ja) 2003-12-19 2005-06-30 Ono Pharmaceutical Co., Ltd. リゾホスファチジン酸受容体拮抗作用を有する化合物およびその用途
WO2006001463A1 (ja) 2004-06-23 2006-01-05 Ono Pharmaceutical Co., Ltd. Ｓ１ｐ受容体結合能を有する化合物およびその用途
CN101370794A (zh) 2006-01-17 2009-02-18 阿斯利康(瑞典)有限公司 化合物
WO2010051053A1 (en) 2008-03-03 2010-05-06 Rxbio, Inc. Lpa receptor agonists and antagonists
WO2012039460A1 (ja) 2010-09-24 2012-03-29 アステラス製薬株式会社 置換アミド化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999019513A2 (en) 1997-10-10 1999-04-22 Lxr Biotechnology, Inc. Methods for detecting compounds which modulate the activity of an lpa receptor
US7294642B2 (en) * 2002-09-06 2007-11-13 Elan Pharmaceuticals, Inc. 1,3-Diamino-2-hydroxypropane pro-drug derivatives
JP5225098B2 (ja) * 2005-12-14 2013-07-03 ブリストル−マイヤーズ スクイブ カンパニー 第ＸＩａ因子インヒビターとしてのアリールプロピオンアミド、アリールアクリルアミド、アリールプロピンアミド、またはアリールメチルウレアアナログ
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
TW201117809A (en) 2009-09-25 2011-06-01 Astellas Pharma Inc Substituted amide compounds

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114505A1 (en) 2000-02-18 2003-06-19 Akihiro Ueno Novel isoxazole and thiazole compounds and use thereof as drugs
WO2001060819A1 (fr) 2000-02-18 2001-08-23 Kirin Beer Kabushiki Kaisha Nouveaux composes d'isoxazole et de thiazole et leur utilisation en tant que medicaments
WO2002062389A1 (fr) 2001-02-08 2002-08-15 Ono Pharmaceutical Co., Ltd. Remedes pour des maladies urinaires contenant des agents de regulation du recepteur de lpa
US20040067908A1 (en) 2001-02-08 2004-04-08 Shinji Nakade Remedies for urinary diseases comprising lpa receptor controlling agents
US20050256160A1 (en) 2002-05-28 2005-11-17 Hiromu Habashita Beta-alanine derivatives and the use thereof
WO2003099765A1 (fr) 2002-05-28 2003-12-04 Ono Pharmaceutical Co., Ltd. Derive de $g(b)-alanine et utilisation correspondante
US20060135577A1 (en) 2002-06-26 2006-06-22 Shinji Nakade Remedy for chronic disease
WO2004002530A1 (ja) 2002-06-26 2004-01-08 Ono Pharmaceutical Co., Ltd. 慢性疾患治療剤
WO2004031118A1 (ja) 2002-10-03 2004-04-15 Ono Pharmaceutical Co., Ltd. Ｌｐａ受容体拮抗剤
US20060148830A1 (en) 2002-10-03 2006-07-06 Ono Pharmaceutical Co., Ltd. Lpa receptor antagonist
US20070149595A1 (en) 2003-12-19 2007-06-28 Motoyuki Tanaka Compounds having lysophosphatidic acid receptor antagonism and uses thereof
EP1695955A1 (en) 2003-12-19 2006-08-30 Ono Pharmaceutical Co., Ltd. Compounds having lysophosphatidic acid receptor antagonism and uses thereof
WO2005058790A1 (ja) 2003-12-19 2005-06-30 Ono Pharmaceutical Co., Ltd. リゾホスファチジン酸受容体拮抗作用を有する化合物およびその用途
WO2006001463A1 (ja) 2004-06-23 2006-01-05 Ono Pharmaceutical Co., Ltd. Ｓ１ｐ受容体結合能を有する化合物およびその用途
US20080207584A1 (en) 2004-06-23 2008-08-28 Ono Pharmaceutical Co., Ltd. Compound Having S1P Receptor Binding Potency and Use Thereof
CN101370794A (zh) 2006-01-17 2009-02-18 阿斯利康(瑞典)有限公司 化合物
JP2009523774A (ja) 2006-01-17 2009-06-25 アストラゼネカ アクチボラグ 化合物
US20100197749A1 (en) 2006-01-17 2010-08-05 Astrazeneca Ab Chemical compounds
WO2010051053A1 (en) 2008-03-03 2010-05-06 Rxbio, Inc. Lpa receptor agonists and antagonists
WO2012039460A1 (ja) 2010-09-24 2012-03-29 アステラス製薬株式会社 置換アミド化合物

Non-Patent Citations (41)

* Cited by examiner, † Cited by third party
Title
Allard, J., et al., "A rat G protein-coupled receptor selectively expressed in myelin-forming cells," European Journal of Neuroscience, vol. 10, pp. 1045-1053, (1998).
American Urological Association Education and Research, Inc., Guideline on the management of benign prostatic hyperplasia (BPH), (2003).
Aoki J., Semin Cell Dev Biol., vol. 15 (2004) pp. 477-489.
Boucharaba A. et al., PNAS, vol. 103, No. 25 (2006) pp. 9643-9648.
Boucharaba, A., et al., "The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases," Proceedings of the National Academy of Science, vol. 103, No. 25, pp. 9643-9648, (Jun. 20, 2006).
Chang et al., International Journal of Urology, vol. 15 (2008) pp. 981-985.
Combined Office Action and Search Report issued Apr. 19, 2013 in Chinese Patent Application No. 201080042593.8 (with English language translation).
Extended European Search Report issued Feb. 15, 2013, in European Patent Application 10818864.0-1452/2481725 PCT/JP2010/066572, filed Sep. 24, 2010 (with English-language Translation).
Guo, C., et al., "Mitogenic Signaling in Androgen Sensitive and Insensitive Prostate Cancer Cell Lines," The Journal of Urology, vol. 163, pp. 1027-1032, (Mar. 2000).
Hama, K., et al., "Lysophosphatidic acid (LPA) receptors are activated differentially by biological fluids: possible role of LPA-binding proteins in activation of LPA receptors," FEBS Letters, vol. 523, pp. 187-192, (2002).
Hedlund and Andersson, Scan J Urol Nephrol, vol. 23 (1989) pp. 251-254.
Hu, Y.L., et al., "Lysophosphatadic Acid Induction of Vascular Endothelial Growth Factor Expression in Human Ovarian Cancer Cells," Journal of the National Cancer Institute, Nol. 93, No. 10, pp. 762-768, (May 16, 2001).
Ikeda, H., et al., "Effects of Lysophosphatidic Acid on Proliferation of Stellate Cells and Hepatocytes in Culture," Biochemical and Biophysical Communications, vol. 248, No. 2, pp. 436-440, (1998).
Imamura, F., et al., "Induction of In Vitro Tumor Cell Invasion of Cellular Monolayers by Lysophosphatidic Acid or Phospholipase D," Biochemical and Biophysical Research Communications, vol. 193, No. 2, pp. 497-503, (Jun. 15, 1993).
Inoue et al., Nature Medicine, vol. 10 (2004) pp. 1-7.
Inoue, M., et al., "Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling," Nature Medicine, vol. 10, No. 7, pp. 712-718, (Jul. 2004).
International Preliminary Report on Patentability and Written Opinion issued Apr. 25, 2013 in PCT/JP2011/071635 filed on Sep. 22, 2011.
International Search Report Issued Nov. 22, 2010 in PCT/JP10/66572 Filed Sep. 24, 2010.
International Search Report issued on Dec. 6, 2011, in PCT/JP2011/071635 filed on Sep. 22, 2011.
Jeon, E.S., et al., "Mesenchymal stem cells stimulate angiogenesis in a murine xenograft model of A549 human adenocarcinoma through an LPA1 receptor-dependent mechanism," Biochimica et Biophysica Acta, vol. 1801, pp. 1205-1213, (2010).
Kropp, B.P., et al., "Characterization of Cultured Bladder Smooth Muscle Cells: Assessment of In Vitro Contractility," The Journal of Urology, vol. 162, pp. 1779-1784, (Nov. 1999).
Kumar, A., et al., "Increased Pro-Nerve Growth Factor and p75 Neurotrophin Receptor Levels in Developing Hypothyroid Rat Cerebral Cortex Are Associated with Enhanced Apoptosis," Endocrinology, vol. 147, No. 10, pp. 4893-4903, (Oct. 2006).
Ma L. et al., J. Neurochem, vol. 109 (2009) pp. 603-610.
Mexican Office Action issued Jul. 22, 2013 in Patent Application No. MX/a/2012/003560 with English Translation.
Nitti V. W. Reviews in Urology, vol. 7 (2005) pp. S12-S17.
Office Action issued Apr. 17, 2013 in Mexican Patent Application No. MX/a/2012/003560 (with English language translation).
Office Action issued Jan. 29, 2013 in Thai Patent Application No. 1201001317 (submitting English Statement of Relevancy).
Office Action issued Sep. 11, 2013 in Israeli Patent Application No. 218723 (with English-language translation).
Pradere et al., Biochimica et Biophysica Acta 1781, (2008) pp. 582-587.
Pradere et al., J Am Soc Nephrol, vol. 18 (2007) pp. 3110-3118.
Pradere, J.P., "LPA1 Receptor Activation Promotes Renal Interstitial Fibrosis," Journal of American Society of Nephrology, vol. 18, pp. 3110-3118, (2007).
Siess, W., et al., "Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions," Proceedings of the National Academy of Science, vol. 96, pp. 6931-6936, (Jun. 1999).
Tager et al., Nature Medicine, vol. 14, No. 1 (2008) pp. 45-54.
Tager, A.M., et al., "The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak," Nature Medicine, vol. 14, No. 1, pp. 45-54, (Jan. 2008).
Watanabe, N., et al., "Both Plasma Lysophosphatidic Acid and Serum Autotaxin Levels are Increased in Chronic Hepatitis C," Journal of Clinical Gastroenterology, vol. 41, No. 6, pp. 616-623, (Jul. 2007).
Watanabe, N., et al., "Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity," Life Sciences, vol. 81, pp. 1009-1015, (2007).
Weiner, J.A., et al., "Lysophosphatidic Acid Receptor Gene vzg-1/1pA1/edg-2 Is Expressed by Mature Oligodendrocytes During Myelination in the Postnatal Murine Brain," The Journal of Comparative Neurology, vol. 398, pp. 587-598, (1998).
Weiner, J.A., et al., "Schwann cell survival mediated by the signaling phospholipid lysophosphatidic acid," Proceedings of the National Academy of Science, vol. 96, pp. 5233-5238, (Apr. 1999).
Xu, Y., et al., "Lysophosphatidic Acid as a Potential Biomarker for Ovarian and other Gynecologic Cancers," JAMA, vol. 280, No. 8, pp. 719-723, (Aug. 26, 1998).
Yanase, M., et al., "Lysophosphatidic Acid Enhances Collagen Gel Contraction by Hepatic Stellate Cells: Association with Rho-Kinase," Biochemical and Biophysical Research Communications, vol. 277, No. 1, pp. 72-78, (2000).
Zeng et al., Prostate, vol. 69 (2009) pp. 1-10.

Also Published As

Publication number Publication date
CA2774647C (en) 2017-03-28
CN102548965B (zh) 2014-04-09
US20120184521A1 (en) 2012-07-19
EP2481725A4 (en) 2013-03-20
IL218723A0 (en) 2012-06-28
KR20120078700A (ko) 2012-07-10
RU2015117267A (ru) 2015-11-10
BR112012006686B1 (pt) 2021-02-09
PT2620433E (pt) 2015-06-22
EP2481725B1 (en) 2015-03-04
CA2774647A1 (en) 2011-03-31
RU2563639C2 (ru) 2015-09-20
PL2481725T3 (pl) 2015-08-31
TW201117809A (en) 2011-06-01
AU2010299114A1 (en) 2012-04-12
MX2012003560A (es) 2012-10-05
EP2481725A1 (en) 2012-08-01
BR112012006686A2 (pt) 2016-05-10
RU2609021C2 (ru) 2017-01-30
PT2481725E (pt) 2015-05-21
JPWO2011037192A1 (ja) 2013-02-21
WO2011037192A1 (ja) 2011-03-31
BR112013006936A2 (pt) 2016-07-19
ES2532866T3 (es) 2015-04-01
ZA201202106B (en) 2013-05-29
JP5708936B2 (ja) 2015-04-30
US20130231320A1 (en) 2013-09-05
KR101678255B1 (ko) 2016-11-21
CN102548965A (zh) 2012-07-04
RU2012116505A (ru) 2013-11-20
US8815920B2 (en) 2014-08-26
BR112012006686B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
US8815920B2 (en) Substituted amide compound
KR101769654B1 (ko) 치환 아미드 화합물
US20090281142A1 (en) Thiazole derivative
RU2732572C2 (ru) Сульфонамидное соединение или его соль
US20090082367A1 (en) Triazole derivative or a salt thereof
TWI317359B (en) N-phenyl-arylsulfonamide compound and the pharmaceuticals containing the same as active ingredient
USRE49111E1 (en) 2-acylaminothiazole derivative or salt thereof
JP5776695B2 (ja) 置換アミド化合物

Legal Events

Date Code Title Description
AS Assignment

Owner name: ASTELLAS PHARMA INC., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KAWAMINAMI, EIJI;TAKAHASHI, TATSUHISA;KANAYAMA, TAKATOSHI;AND OTHERS;REEL/FRAME:027946/0143

Effective date: 20120224

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551)

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8